Page last updated: 2024-12-06

sulfametrole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N1-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfametrole : A sulfonamide obtained by formal condensation of the sulfo group of 4-aminobenzenesulfonic acid with the amino group of 4-methoxy-1,2,5-thiadiazol-3-amine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID64939
CHEMBL ID2105398
CHEBI ID88258
SCHEMBL ID148552
MeSH IDM0058763

Synonyms (36)

Synonym
sulfametrole
4-amino-n-(4-methoxy-1,2,5-thiadiazol-3-yl)benzenesulfonamide
D08541
lidaprim (tn)
sulfametrole (inn)
32909-92-5
CHEMBL2105398
sulfametrol [inn-spanish]
einecs 251-288-1
sulfametrolum [inn-latin]
unii-f5ak41ipqg
4-amino-n-(5-methoxy-2,1,3-thiadiazol-4-yl)benzolsulfonamid
n1-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide
f5ak41ipqg ,
n(sup 1)-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide
sulfametrol
sulfametrolum
sulfametrole [inn:ban]
SCHEMBL148552
sulfametrole [inn]
sulfametrole [mart.]
sulfametrole [who-dd]
sulfametrole [mi]
IZOYMGQQVNAMHS-UHFFFAOYSA-N
3-methoxy-4-(4'-aminobenzenesulfonamido)-1,2,5-thiadiazole
3-methoxy-4-(4'-aminobenzene-sulfonamido)-1,2,5-thiadiazole
4-amino-n-(4-methoxy-1,2,5-thiadiazol-3-yl)benzene-1-sulfonamide
CHEBI:88258
FT-0727929
gtpl12702
Q7636179
DTXSID40865655
benzenesulfonamide, 4-amino-n-(4-methoxy-1,2,5-thiadiazol-3-yl)-; sulfanilamide, n1-(4-methoxy-1,2,5-thiadiazol-3-yl)- (7ci,8ci); 1,2,5-thiadiazole, benzenesulfonamide deriv.; 4-amino-n-(4-methoxy-1,2,5-thiadiazol-3-yl)benzenesulfonamide; sulfametrole
CS-0135813
HY-133937
n1-(4-methoxy-1,2,5-thiadiazol-3-yl)-sulfanilamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Inadequate therapeutic results in the treatment of bacterial infections in patients with Cystic Fibrosis prompted a reevaluation of pharmacokinetic parameters of orally and parenterally administered drugs in these patients."( [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].
Guggenbichler, JP; Pillwein, K; Rohrer, R; Schabel, F, 1981
)
0.26
" In addition, a population pharmacokinetic model using plasma data was built."( Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy.
Bellmann, R; Bellmann-Weiler, R; Beyer, R; Broeker, A; Eschertzhuber, S; Gasperetti, T; Hotter, J; Joannidis, M; Lorenz, I; Ranke, P; Ströhle, M; Welte, R; Wicha, SG; Zaruba, MM, 2020
)
0.84
" The population pharmacokinetic analysis indicated that neither CRRT intensity nor residual diuresis were significant covariates on trimethoprim or sulfametrole CL."( Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy.
Bellmann, R; Bellmann-Weiler, R; Beyer, R; Broeker, A; Eschertzhuber, S; Gasperetti, T; Hotter, J; Joannidis, M; Lorenz, I; Ranke, P; Ströhle, M; Welte, R; Wicha, SG; Zaruba, MM, 2020
)
1.04

Dosage Studied

ExcerptRelevanceReference
"Women with genital ulcer disease who were culture-positive for Haemophilus ducreyi were treated with a single dose of the drug combination trimethoprim-sulfametrole; the dosage was 640 mg of trimethoprim and 3,200 mg of sulfametrole."( Single-dose therapy with trimethoprim-sulfametrole for chancroid in females.
D'Costa, LJ; Dylewski, J; Nsanze, H; Ronald, AR,
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
thiadiazoles
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (52.63)18.7374
1990's2 (10.53)18.2507
2000's3 (15.79)29.6817
2010's3 (15.79)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.85 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (17.39%)5.53%
Reviews4 (17.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (65.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]